In low- and middle-income countries, infectious diseases—ranging from diarrheal disease and malaria to neglected tropical diseases—present serious health challenges. In collaboration with country, industry, and public- and private-sector stakeholders worldwide, PATH advances vaccines, drugs, diagnostics, devices, and systems and service innovations to address these illnesses and protect health. The Drug Development program is key to these efforts.
Our strategy focuses on:
- Prioritizing illnesses and conditions that disproportionately affect the world’s most vulnerable populations, particularly women and children.
- Identifying and developing promising drug candidates by focusing leading science and public health expertise on those illnesses.
- Exploring innovative financing mechanisms and analyzing market dynamics to ensure products are available, accessible, and affordable at the national and individual level.
We advance our efforts by:
- Fostering partnerships. As a trusted convener, we mobilize and align leading experts and organizations from the academic, private, public, and nonprofit sectors to achieve shared scientific and humanitarian goals. By coordinating efforts and facilitating dialogue between like-minded individuals and institutions, we bring the best resources, expertise, and strengths to the work of drug development, amplifying our collective ability to protect health and save lives.
- Working across the value chain. To save lives, a drug must not only exist, but also reach the people who need it. We work across the value chain to shepherd new tools and approaches through the journey of innovation—developing and testing solutions, navigating regulatory pathways for approval, addressing barriers to acceptance and use, and supporting countries and communities as they introduce new tools—to achieve successful, widespread uptake and sustainable impact.